110 related articles for article (PubMed ID: 20356698)
21. Genotypic and phenotypic relationship in Burkholderia pseudomallei indicates colonization with closely related isolates.
Radu S; Lihan S; Idris A; Ling OW; Al-Haddawi MH; Rusul G
Southeast Asian J Trop Med Public Health; 1999 Dec; 30(4):760-3. PubMed ID: 10928372
[TBL] [Abstract][Full Text] [Related]
22. Case Series Study of Melioidosis, Colombia.
Rodríguez JY; Morales-López SE; Rodríguez GJ; Álvarez-Moreno CA; Esquea K; Pinzon H; Ramirez LR; Moreno L; Ocampo W; Cepeda ML
Emerg Infect Dis; 2019 Aug; 25(8):1531-4. PubMed ID: 31310232
[TBL] [Abstract][Full Text] [Related]
23. Presence of tetracycline resistance determinants and susceptibility to tigecycline and minocycline.
Fluit AC; Florijn A; Verhoef J; Milatovic D
Antimicrob Agents Chemother; 2005 Apr; 49(4):1636-8. PubMed ID: 15793159
[TBL] [Abstract][Full Text] [Related]
24. Variations in ceftazidime and amoxicillin-clavulanate susceptibilities within a clonal infection of Burkholderia pseudomallei.
Sam IC; See KH; Puthucheary SD
J Clin Microbiol; 2009 May; 47(5):1556-8. PubMed ID: 19297597
[TBL] [Abstract][Full Text] [Related]
25. Mycotic aneurysm in Northeast Thailand: the importance of Burkholderia pseudomallei as a causative pathogen.
Anunnatsiri S; Chetchotisakd P; Kularbkaew C
Clin Infect Dis; 2008 Dec; 47(11):1436-9. PubMed ID: 18937581
[TBL] [Abstract][Full Text] [Related]
26. Susceptibility of Pseudomonas pseudomallei to some newer beta-lactam antibiotics and antibiotic combinations using time-kill studies.
Smith MD; Wuthiekanun V; Walsh AL; White NJ
J Antimicrob Chemother; 1994 Jan; 33(1):145-9. PubMed ID: 7512547
[No Abstract] [Full Text] [Related]
27. Antimicrobial susceptibility pattern of clinical isolates of Burkholderia pseudomallei in Bangladesh.
Dutta S; Haq S; Hasan MR; Haq JA
BMC Res Notes; 2017 Jul; 10(1):299. PubMed ID: 28728591
[TBL] [Abstract][Full Text] [Related]
28. In vitro activity of tigecycline and 10 other antimicrobials against clinical isolates of the genus Corynebacterium.
Fernandez-Roblas R; Adames H; Martín-de-Hijas NZ; Almeida DG; Gadea I; Esteban J
Int J Antimicrob Agents; 2009 May; 33(5):453-5. PubMed ID: 19153032
[TBL] [Abstract][Full Text] [Related]
29. In-vitro susceptibility of Burkholderia pseudomallei to cefoperazone-sulbactam combination.
Koay AS; Rohani MY; Cheong YM
Med J Malaysia; 1997 Jun; 52(2):158-60. PubMed ID: 10968074
[TBL] [Abstract][Full Text] [Related]
30. In vitro antimicrobial susceptibility of clinical and environmental strains of Burkholderia pseudomallei from Brazil.
Bandeira Tde J; Brilhante RS; Rocha MF; Moreira CA; Cordeiro Rde A; Ribeiro JF; Castelo-Branco Dde S; Sidrim JJ
Int J Antimicrob Agents; 2013 Oct; 42(4):375-7. PubMed ID: 23993065
[No Abstract] [Full Text] [Related]
31. In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
Cercenado E; Marín M; Sánchez-Martínez M; Cuevas O; Martínez-Alarcón J; Bouza E
Antimicrob Agents Chemother; 2007 Mar; 51(3):1102-4. PubMed ID: 17194827
[TBL] [Abstract][Full Text] [Related]
32. Tigecycline: its potential for treatment of brucellosis.
Dizbay M; Kilic S; Hizel K; Arman D
Scand J Infect Dis; 2007; 39(5):432-4. PubMed ID: 17464866
[TBL] [Abstract][Full Text] [Related]
33. In vitro interactions between cotrimoxazole and doxycycline in Burkholderia pseudomallei: how important is this combination in maintenance therapy of melioidosis?
Saraya S; Soontornpas C; Chindavijak B; Mootsikapun P
Indian J Med Microbiol; 2009; 27(1):88-9. PubMed ID: 19172079
[No Abstract] [Full Text] [Related]
34. Activity of five fluoroquinolones against 71 isolates of Burkholderia pseudomallei.
Ho PL; Cheung TK; Kinoshita R; Tse CW; Yuen KY; Chau PY
J Antimicrob Chemother; 2002 Jun; 49(6):1042-4. PubMed ID: 12039903
[No Abstract] [Full Text] [Related]
35. Melioidosis masquerading as enteric fever.
Valsalan R; Seshadri S; Pandit VR
Trans R Soc Trop Med Hyg; 2008 Dec; 102 Suppl 1():S117-8. PubMed ID: 19121671
[TBL] [Abstract][Full Text] [Related]
36. Burkholderia pseudomallei animal and human isolates from Malaysia exhibit different phenotypic characteristics.
Lee SH; Chong CE; Lim BS; Chai SJ; Sam KK; Mohamed R; Nathan S
Diagn Microbiol Infect Dis; 2007 Jul; 58(3):263-70. PubMed ID: 17350202
[TBL] [Abstract][Full Text] [Related]
37. In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002.
Bouchillon SK; Hoban DJ; Johnson BM; Stevens TM; Dowzicky MJ; Wu DH; Bradford PA
Diagn Microbiol Infect Dis; 2005 Apr; 51(4):291-5. PubMed ID: 15808321
[TBL] [Abstract][Full Text] [Related]
38. [Problems of resistance of the causative agent of melioidosis to antibiotics].
Antonov IuV; Popovtseva LD; Iarulin RG; Iliukhin VI; Lozovaia NA; Farber SM; Knirel' IuA; Varbanets LD
Antibiot Khimioter; 1991 Oct; 36(10):26-8. PubMed ID: 1725248
[TBL] [Abstract][Full Text] [Related]
39. In vitro activity of tigecycline against Bacteroides species.
Betriu C; Culebras E; Gómez M; Rodríguez-Avial I; Picazo JJ
J Antimicrob Chemother; 2005 Aug; 56(2):349-52. PubMed ID: 15951353
[TBL] [Abstract][Full Text] [Related]
40. In vitro activity of tigecycline (GAR-936), a novel glycylcycline, against vancomycin-resistant enterococci and staphylococci with diminished susceptibility to glycopeptides.
Cercenado E; Cercenado S; Gómez JA; Bouza E
J Antimicrob Chemother; 2003 Jul; 52(1):138-9. PubMed ID: 12805264
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
